The Inhalation Anesthetic Desflurane Induces Caspase Activation and Increases Amyloid β-Protein Levels under Hypoxic Conditions

Abstract

Perioperative factors including hypoxia, hypocapnia, and certain anesthetics have been suggested to contribute to Alzheimer disease (AD) neuropathogenesis. Desflurane is one of the most commonly used inhalation anesthetics. However, the effects of desflurane on AD neuropathogenesis have not been previously determined. Here, we set out to assess the effects of desflurane and hypoxia on caspase activation, amyloid precursor protein (APP) processing, and amyloid β-protein (Aβ) generation in H4 human neuroglioma cells (H4 naïve cells) as well as those overexpressing APP (H4-APP cells). Neither 12% desflurane nor hypoxia (18% O2) alone affected caspase-3 activation, APP processing, and Aβ generation. However, treatment with a combination of 12% desflurane and hypoxia (18% O2) (desflurane/hypoxia) for 6 h induced caspase-3 activation, altered APP processing, and increased Aβ generation in H4-APP cells. Desflurane/hypoxia also increased levels of β-site APP-cleaving enzyme in H4-APP cells. In addition, desflurane/hypoxia-induced Aβ generation could be reduced by the broad caspase inhibitor benzyloxycarbonyl-VAD. Finally, the Aβ aggregation inhibitor clioquinol and γ-secretase inhibitor L-685,458 caspase-3 induced by In desflurane Aβ and caspase activation, in the of in have for in and those with Perioperative factors including hypoxia, hypocapnia, and certain anesthetics have been suggested to contribute to Alzheimer disease (AD) neuropathogenesis. Desflurane is one of the most commonly used inhalation anesthetics. However, the effects of desflurane on AD neuropathogenesis have not been previously determined. Here, we set out to assess the effects of desflurane and hypoxia on caspase activation, amyloid precursor protein (APP) processing, and amyloid β-protein (Aβ) generation in H4 human neuroglioma cells (H4 naïve cells) as well as those overexpressing APP (H4-APP cells). Neither 12% desflurane nor hypoxia (18% O2) alone affected caspase-3 activation, APP processing, and Aβ generation. However, treatment with a combination of 12% desflurane and hypoxia (18% O2) (desflurane/hypoxia) for 6 h induced caspase-3 activation, altered APP processing, and increased Aβ generation in H4-APP cells. Desflurane/hypoxia also increased levels of β-site APP-cleaving enzyme in H4-APP cells. In addition, desflurane/hypoxia-induced Aβ generation could be reduced by the broad caspase inhibitor benzyloxycarbonyl-VAD. Finally, the Aβ aggregation inhibitor clioquinol and γ-secretase inhibitor L-685,458 caspase-3 induced by In desflurane Aβ and caspase activation, in the of in have for in and those with have suggested and of Alzheimer disease (AD) used Alzheimer amyloid precursor β-site APP-cleaving amyloid not used Alzheimer amyloid precursor β-site APP-cleaving amyloid not also increased for AD as with those by and of amyloid β-protein (Aβ) a in the of AD in and Aβ is of amyloid precursor protein (APP) by β-site APP-cleaving enzyme APP to a is by γ-secretase to Aβ and precursor protein and γ-secretase as a and of and for γ-secretase is with a of including AD in Aβ been to caspase and in Aβ generation Finally, of Aβ and of Aβ including hypoxia and anesthetics have been to contribute to AD neuropathogenesis. factors also a with and by AD and desflurane the most commonly used inhalation anesthetics. been the and of Aβ and have a of to caspase-3 activation, APP processing, and Aβ generation in human H4 neuroglioma cells overexpressing human APP and not caspase and in human However, effects of desflurane and desflurane hypoxia, on APP and Aβ generation have not been the we set out to effects of hypoxia, and the combination of the (desflurane/hypoxia) on caspase-3 activation, APP processing, and Aβ generation in H4 human neuroglioma cells (H4 naïve cells) and H4 naïve cells to APP (H4-APP cells). also the caspase the γ-secretase inhibitor and the Aβ aggregation inhibitor clioquinol could desflurane/hypoxia-induced caspase-3 and Aβ H4 human neuroglioma cells (H4 naïve cells) and H4 naïve cells to APP (H4-APP cells) in the of the in and H4 cells with cells for 6 h with desflurane alone and 12% hypoxia alone (18% and and (18% and 12% not caspase-3 activation, APP processing, and Aβ generation used to In the the cells with L-685,458 clioquinol and h for and the for Aβ for hypoxia, and not caspase-3 activation, APP processing, and Aβ generation not and on for and for by protein cells the of the and to as by and of and used to and used to caspase-3 used to and caspase-3 used to protein levels of of as by of by the of we used levels of to of to levels of caspase-3 and to for in protein we in levels of caspase-3 and in cells as a of those in cells with of Aβ Aβ with a by Aβ and by the Aβ the for of as by with to with with of and to with and well Aβ levels in by with with of and the of caspase-3 and in cells in we not to in caspase-3 caspase-3 activation, and in the to levels for the of to as the of to and the used a to and and APP Aβ in H4-APP previously and Aβ levels in H4-APP cells effects of commonly used inhalation including and on APP processing, and Aβ generation have not been set out to effects in H4-APP cells. caspase-3 is one of the of we effects of desflurane on caspase-3 by In the treatment with 12% desflurane for 6 h induced caspase-3 as by the of caspase-3 to of the on the of caspase-3 to the desflurane treatment not caspase-3 as with APP in levels of and and H4-APP cells Finally, the desflurane treatment not levels of as with desflurane alone nor Aβ APP and Aβ in H4-APP hypoxia been to AD neuropathogenesis we the effects of on caspase-3 activation, APP processing, and Aβ levels in H4-APP cells. to assess the effects of desflurane on and Aβ generation in protein levels of caspase-3 treatment with 12% for 6 h as with of the by of caspase-3 to treatment to a in caspase-3 as with APP in protein levels of not the treatment as with of the the treatment to a in levels of as with Finally, the treatment increased and the combination of desflurane and hypoxia APP processing, and Aβ caspase-3 activation, APP processing, and Aβ levels in H4-APP cells. treatment with 12% for 6 h caspase-3 as with in H4-APP cells. is in the of in H4-APP cells. of the treatment caspase-3 with to and levels of not as with in H4-APP cells. is in of in H4-APP cells. of the not levels of as with to of the levels of as with to generation of and as with the the and Aβ we the desflurane/hypoxia-induced in APP and Aβ generation is on caspase-3 we set out to assess the effects of the caspase inhibitor on desflurane/hypoxia-induced caspase-3 and Aβ generation. treatment caspase-3 induced by alone not caspase-3 as with of the desflurane/hypoxia-induced caspase-3 also reduced desflurane/hypoxia-induced in Aβ levels in H4-APP inhibitor caspase-3 induced by in H4-APP cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and treatment and treatment and caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is reduced by treatment Aβ levels in H4-APP cells as with the desflurane/hypoxia-induced in Aβ levels in H4-APP cells we caspase-3 in the of APP in naïve H4 cells. induced caspase-3 as with in H4 naïve and H4-APP cells of the treatment to a and a in caspase-3 as with in H4 naïve cells and H4-APP cells APP not in levels of and treatment and in H4 naïve cells a APP reduced levels of in levels as with in H4-APP cells of the treatment not the of to in H4 naïve cells to a in the of to in H4-APP cells Aβ levels to be in H4 naïve cells in not caspase-3 in the of in APP and Aβ generation in H4 naïve desflurane/hypoxia-induced in Aβ generation on the desflurane/hypoxia-induced caspase-3 in H4-APP treatment caspase-3 of APP in H4 naïve cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and in H4 naïve cells. treatment and also caspase-3 in H4-APP cells as with and of the caspase-3 as with to in H4 naïve cells. of the caspase-3 as with to in H4-APP cells. not levels of as with in H4 naïve cells. Desflurane/hypoxia levels of as with in H4-APP cells. of the not of to as with in H4 naïve cells of the of to in H4-APP cells of in H4-APP levels of with 12% (18% O2) for 6 h in levels as with of the treatment to a in levels as with caspase-3 and Aβ generation by levels of in H4-APP cells. and levels of as with is in of in H4-APP cells. of the levels as with to by the L-685,458 the Aβ by in Aβ generation Aβ aggregation desflurane/hypoxia-induced caspase-3 we the effects of the γ-secretase inhibitor L-685,458 and Aβ aggregation on desflurane/hypoxia-induced caspase-3 in H4-APP cells. L-685,458 reduced caspase-3 induced by and L-685,458 alone not caspase-3 levels as with and L-685,458 in Aβ treatment to of desflurane/hypoxia-induced caspase-3 and alone not caspase-3 as with and Finally, we a could desflurane/hypoxia-induced caspase-3 to the Aβ treatment desflurane/hypoxia-induced caspase-3 in H4 naïve and treatment of Aβ generation and inhibitor L-685,458 and Aβ aggregation inhibitor the desflurane/hypoxia-induced caspase-3 activation, Aβ the desflurane/hypoxia-induced caspase-3 in H4-APP cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and L-685,458 treatment and L-685,458 treatment and caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is reduced by L-685,458 L-685,458 the desflurane/hypoxia-induced in and levels in H4-APP cells. and caspase-3 as with and treatment and and treatment caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is by treatment of caspase-3 as with treatment caspase-3 induced by is in of in H4-APP cells with the of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is by treatment of Aβ (18% O2) APP Aβ in H4-APP we hypoxia alone also caspase-3 activation, APP processing, and Aβ generation in H4-APP cells. with hypoxia (18% O2) for 6 h not caspase-3 and not APP and not Aβ generation the APP and Aβ generation induced by most to effects of not caspase-3 activation, APP processing, nor Aβ generation in H4-APP cells. hypoxia treatment alone not caspase-3 as with in H4-APP cells. is in of in H4-APP cells. of the hypoxia treatment not caspase-3 with to hypoxia not APP as with in H4-APP cells. is in of in H4-APP cells. of the hypoxia treatment not levels of as with to of the hypoxia treatment not levels of as with to hypoxia not generation of as with commonly used inhalation previously been to Aβ aggregation and to of Aβ have and Aβ generation in H4-APP cells desflurane is commonly used inhalation we set out to assess the effects of desflurane on APP processing, and Aβ generation in H4-APP cells. to a treatment with a of desflurane not caspase-3 and affected APP nor Aβ levels in H4-APP cells. with of and not However, is of desflurane in to and of Aβ we treatment with 12% (18% O2) for 6 h caspase-3 activation, APP processing, and Aβ generation in H4-APP treatment with 12% desflurane hypoxia alone not to effects in H4-APP cells. desflurane AD neuropathogenesis is treatment with 12% desflurane alone for 6 h effects on and by and in for one and in be to in desflurane is used as inhalation to assess the effects of desflurane on and Aβ generation be to assess alone have effects on and Aβ a broad caspase to caspase-3 and Aβ generation induced by the desflurane/hypoxia-induced in APP and Aβ generation on the of to the by APP processing, and Aβ we the effects of on Desflurane/hypoxia treatment for 6 h increased protein levels of in H4-APP cells. we inhalation in levels to APP and to Aβ generation have to caspase in protein levels of protein a protein and of is with increased levels of and of is to and levels of to levels and to caspase have previously amyloid a and a protein Aβ induced by of Aβ aggregation and generation desflurane/hypoxia-induced caspase-3 in H4-APP cells by the effects of Aβ aggregation and L-685,458 γ-secretase on caspase-3 induced by in H4-APP cells. L-685,458 caspase-3 and Aβ generation induced by also induced by in Aβ generation and aggregation desflurane/hypoxia-induced treatment with Aβ desflurane/hypoxia-induced caspase-3 activation, a of and Aβ generation be by we have the combination of desflurane and hypoxia, APP processing, and Aβ generation. a in to in and Aβ Aβ levels to caspase activation, in a in be to assess the of desflurane hypoxia in AD neuropathogenesis. to the effects of anesthetics on AD to of to to the of and for by a of and Aβ Desflurane/hypoxia caspase-3 activation, in to Aβ generation. Desflurane/hypoxia also Aβ caspase-3 and Aβ generation and Aβ aggregation to a of desflurane/hypoxia-induced and Aβ have suggested and of Alzheimer disease (AD) used Alzheimer amyloid precursor β-site APP-cleaving amyloid not used Alzheimer amyloid precursor β-site APP-cleaving amyloid not also increased for AD as with those by and of amyloid β-protein (Aβ) a in the of AD in and Aβ is of amyloid precursor protein (APP) by β-site APP-cleaving enzyme APP to a is by γ-secretase to Aβ and precursor protein and γ-secretase as a and of and for γ-secretase is with a of including AD in Aβ been to caspase and in Aβ generation Finally, of Aβ and of Aβ Perioperative including hypoxia and anesthetics have been to contribute to AD neuropathogenesis. factors also a with and by AD neuropathogenesis. and desflurane the most commonly used inhalation anesthetics. been the and of Aβ and have a of to caspase-3 activation, APP processing, and Aβ generation in human H4 neuroglioma cells overexpressing human APP and not caspase and in human However, effects of desflurane and desflurane hypoxia, on APP and Aβ generation have not been In the we set out to effects of hypoxia, and the combination of the (desflurane/hypoxia) on caspase-3 activation, APP processing, and Aβ generation in H4 human neuroglioma cells (H4 naïve cells) and H4 naïve cells to APP (H4-APP cells). also the caspase the γ-secretase inhibitor and the Aβ aggregation inhibitor clioquinol could desflurane/hypoxia-induced caspase-3 and Aβ generation. H4 human neuroglioma cells (H4 naïve cells) and H4 naïve cells to APP (H4-APP cells) in the of the in and H4 cells with cells for 6 h with desflurane alone and 12% hypoxia alone (18% and and (18% and 12% not caspase-3 activation, APP processing, and Aβ generation used to In the the cells with L-685,458 clioquinol and h for and the for Aβ for hypoxia, and not caspase-3 activation, APP processing, and Aβ generation not and on for and for by protein cells the of the and to as by and of and used to and used to caspase-3 used to and caspase-3 used to protein levels of of as by of by the of we used levels of to of to levels of caspase-3 and to for in protein we in levels of caspase-3 and in cells as a of those in cells with of Aβ Aβ with a by Aβ and by the Aβ the for of as by with to with with of and to with and well Aβ levels in by with with of and the of caspase-3 and in cells in we not to in caspase-3 caspase-3 activation, and in the to levels for the of to as the of to and the used a to and and H4 human neuroglioma cells (H4 naïve cells) and H4 naïve cells to APP (H4-APP cells) in the of the in and H4 cells with cells for 6 h with desflurane alone and 12% hypoxia alone (18% and and (18% and 12% not caspase-3 activation, APP processing, and Aβ generation used to In the the cells with L-685,458 clioquinol and h for and the for Aβ for hypoxia, and not caspase-3 activation, APP processing, and Aβ generation not and on for and for by protein cells the of the and to as by and of and used to and used to caspase-3 used to and caspase-3 used to protein levels of of as by of by the of we used levels of to of to levels of caspase-3 and to for in protein we in levels of caspase-3 and in cells as a of those in cells with of Aβ Aβ with a by Aβ and by the Aβ the for of as by with to with with of and to with and well Aβ levels in by with with of and the of caspase-3 and in cells in we not to in caspase-3 caspase-3 activation, and in the to levels for the of to as the of to and the used a to and and APP Aβ in H4-APP previously and Aβ levels in H4-APP cells effects of commonly used inhalation including and on APP processing, and Aβ generation have not been set out to effects in H4-APP cells. caspase-3 is one of the of we effects of desflurane on caspase-3 by In the treatment with 12% desflurane for 6 h induced caspase-3 as by the of caspase-3 to of the on the of caspase-3 to the desflurane treatment not caspase-3 as with APP in levels of and and H4-APP cells Finally, the desflurane treatment not levels of as with desflurane alone nor Aβ APP and Aβ in H4-APP hypoxia been to AD neuropathogenesis we the effects of on caspase-3 activation, APP processing, and Aβ levels in H4-APP cells. to assess the effects of desflurane on and Aβ generation in protein levels of caspase-3 treatment with 12% for 6 h as with of the by of caspase-3 to treatment to a in caspase-3 as with APP in protein levels of not the treatment as with of the the treatment to a in levels of as with Finally, the treatment increased and the combination of desflurane and hypoxia APP processing, and Aβ the the and Aβ we the desflurane/hypoxia-induced in APP and Aβ generation is on caspase-3 we set out to assess the effects of the caspase inhibitor on desflurane/hypoxia-induced caspase-3 and Aβ generation. treatment caspase-3 induced by alone not caspase-3 as with of the desflurane/hypoxia-induced caspase-3 also reduced desflurane/hypoxia-induced in Aβ levels in H4-APP inhibitor caspase-3 induced by in H4-APP cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and treatment and treatment and caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is reduced by treatment Aβ levels in H4-APP cells as with the desflurane/hypoxia-induced in Aβ levels in H4-APP cells we caspase-3 in the of APP in naïve H4 cells. induced caspase-3 as with in H4 naïve and H4-APP cells of the treatment to a and a in caspase-3 as with in H4 naïve cells and H4-APP cells APP not in levels of and treatment and in H4 naïve cells a APP reduced levels of in levels as with in H4-APP cells of the treatment not the of to in H4 naïve cells to a in the of to in H4-APP cells Aβ levels to be in H4 naïve cells in not caspase-3 in the of in APP and Aβ generation in H4 naïve desflurane/hypoxia-induced in Aβ generation on the desflurane/hypoxia-induced caspase-3 in H4-APP treatment caspase-3 of APP in H4 naïve cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and in H4 naïve cells. treatment and also caspase-3 in H4-APP cells as with and of the caspase-3 as with to in H4 naïve cells. of the caspase-3 as with to in H4-APP cells. not levels of as with in H4 naïve cells. Desflurane/hypoxia levels of as with in H4-APP cells. of the not of to as with in H4 naïve cells of the of to in H4-APP cells of in H4-APP levels of with 12% (18% O2) for 6 h in levels as with of the treatment to a in levels as with caspase-3 and Aβ generation by levels of in H4-APP cells. and levels of as with is in of in H4-APP cells. of the levels as with to by the L-685,458 the Aβ by in Aβ generation Aβ aggregation desflurane/hypoxia-induced caspase-3 we the effects of the γ-secretase inhibitor L-685,458 and Aβ aggregation on desflurane/hypoxia-induced caspase-3 in H4-APP cells. L-685,458 reduced caspase-3 induced by and L-685,458 alone not caspase-3 levels as with and L-685,458 in Aβ treatment to of desflurane/hypoxia-induced caspase-3 and alone not caspase-3 as with and Finally, we a could desflurane/hypoxia-induced caspase-3 to the Aβ treatment desflurane/hypoxia-induced caspase-3 in H4 naïve and treatment of Aβ generation and inhibitor L-685,458 and Aβ aggregation inhibitor the desflurane/hypoxia-induced caspase-3 activation, Aβ the desflurane/hypoxia-induced caspase-3 in H4-APP cells. treatment with desflurane hypoxia for 6 h and caspase-3 as with and L-685,458 treatment and L-685,458 treatment and caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is reduced by L-685,458 L-685,458 the desflurane/hypoxia-induced in and levels in H4-APP cells. and caspase-3 as with and treatment and and treatment caspase-3 induced by is in of in H4-APP cells with of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is by treatment of caspase-3 as with treatment caspase-3 induced by is in of in H4-APP cells with the of the caspase-3 as with to desflurane/hypoxia-induced caspase-3 is by treatment of Aβ (18% O2) APP Aβ in H4-APP we hypoxia alone also caspase-3 activation, APP processing, and Aβ generation in H4-APP cells. with hypoxia (18% O2) for 6 h not caspase-3 and not APP and not Aβ generation the APP and Aβ generation induced by most to effects of not caspase-3 activation, APP processing, nor Aβ generation in H4-APP cells. hypoxia treatment alone not caspase-3 as with in H4-APP cells. is in of in H4-APP cells. of the hypoxia treatment not caspase-3 with to hypoxia not APP as with in H4-APP cells. is in of in H4-APP cells. of the hypoxia treatment not levels of as with to of the hypoxia treatment not levels of as with to hypoxia not generation of as with Desflurane APP Aβ in H4-APP previously and Aβ levels in H4-APP cells effects of commonly used inhalation including and on APP processing, and Aβ generation have not been set out to effects in H4-APP cells. caspase-3 is one of the of we effects of desflurane on caspase-3 by In the treatment with 12% desflurane for 6 h induced caspase-3 as by the of caspase-3 to of the on the of caspase-3 to the desflurane treatment not caspase-3 as with APP in levels of and and H4-APP cells Finally, the desflurane treatment not levels of as with desflurane alone nor Aβ generation. APP and Aβ in H4-APP hypoxia been to AD neuropathogenesis we the effects of on caspase-3 activation, APP processing, and Aβ levels in H4-APP cells. to assess the effects of desflurane on and Aβ generation in protein levels of caspase-3 treatment with 12% for 6 h as with of the by of caspase-3 to treatment to a in caspase-3 as with APP in protein levels of not the treatment as with of the the treatment to a in levels of as with Finally, the treatment increased and the combination of desflurane and hypoxia APP processing, and Aβ generation. the the and Aβ we the desflurane/hypoxia-induced in APP and Aβ generation is on caspase-3 we set out to assess the effects of the caspase inhibitor on desflurane/hypoxia-induced caspase-3 and Aβ generation. treatment caspase-3 induced by alone not caspase-3 as with of the desflurane/hypoxia-induced caspase-3 also reduced desflurane/hypoxia-induced in Aβ levels in H4-APP we caspase-3 in the of APP in naïve H4 cells. induced caspase-3 as with in H4 naïve and H4-APP cells of the treatment to a and a in caspase-3 as with in H4 naïve cells and H4-APP cells APP not in levels of and treatment and in H4 naïve cells a APP reduced levels of in levels as with in H4-APP cells of the treatment not the of to in H4 naïve cells to a in the of to in H4-APP cells Aβ levels to be in H4 naïve cells in not caspase-3 in the of in APP and Aβ generation in H4 naïve desflurane/hypoxia-induced in Aβ generation on the desflurane/hypoxia-induced caspase-3 in H4-APP cells. of in H4-APP levels of with 12% (18% O2) for 6 h in levels as with of the treatment to a in levels as with caspase-3 and Aβ generation by by the L-685,458 the Aβ by in Aβ generation Aβ aggregation desflurane/hypoxia-induced caspase-3 we the effects of the γ-secretase inhibitor L-685,458 and Aβ aggregation on desflurane/hypoxia-induced caspase-3 in H4-APP cells. L-685,458 reduced caspase-3 induced by and L-685,458 alone not caspase-3 levels as with and L-685,458 in Aβ treatment to of desflurane/hypoxia-induced caspase-3 and alone not caspase-3 as with and Finally, we a could desflurane/hypoxia-induced caspase-3 to the Aβ treatment desflurane/hypoxia-induced caspase-3 in H4 naïve and treatment of Aβ generation and (18% O2) APP Aβ in H4-APP we hypoxia alone also caspase-3 activation, APP processing, and Aβ generation in H4-APP cells. with hypoxia (18% O2) for 6 h not caspase-3 and not APP and not Aβ generation the APP and Aβ generation induced by most to effects of commonly used inhalation previously been to Aβ aggregation and to of Aβ have and Aβ generation in H4-APP cells desflurane is commonly used inhalation we set out to assess the effects of desflurane on APP processing, and Aβ generation in H4-APP cells. to a treatment with a of desflurane not caspase-3 and affected APP nor Aβ levels in H4-APP cells. with of and not However, is of desflurane in to and of Aβ we treatment with 12% (18% O2) for 6 h caspase-3 activation, APP processing, and Aβ generation in H4-APP treatment with 12% desflurane hypoxia alone not to effects in H4-APP cells. desflurane AD neuropathogenesis is treatment with 12% desflurane alone for 6 h effects on and by and in for one and in be to in desflurane is used as inhalation to assess the effects of desflurane on and Aβ generation be to assess alone have effects on and Aβ a broad caspase to caspase-3 and Aβ generation induced by the desflurane/hypoxia-induced in APP and Aβ generation on the of to the by APP processing, and Aβ we the effects of on Desflurane/hypoxia treatment for 6 h increased protein levels of in H4-APP cells. we inhalation in levels to APP and to Aβ generation have to caspase in protein levels of protein a protein and of is with increased levels of and of is to and levels of to levels and to caspase have previously amyloid a and a protein Aβ induced by of Aβ aggregation and generation desflurane/hypoxia-induced caspase-3 in H4-APP cells by the effects of Aβ aggregation and L-685,458 γ-secretase on caspase-3 induced by in H4-APP cells. L-685,458 caspase-3 and Aβ generation induced by also induced by in Aβ generation and aggregation desflurane/hypoxia-induced treatment with Aβ desflurane/hypoxia-induced caspase-3 activation, a of and Aβ generation be by we have the combination of desflurane and hypoxia, APP processing, and Aβ generation. a in to in and Aβ Aβ levels to caspase activation, in a in be to assess the of desflurane hypoxia in AD neuropathogenesis. to the effects of anesthetics on AD to of to to the of and for commonly used inhalation previously been to Aβ aggregation and to of Aβ have and Aβ generation in H4-APP cells desflurane is commonly used inhalation we set out to assess the effects of desflurane on APP processing, and Aβ generation in H4-APP cells. to a treatment with a of desflurane not caspase-3 and affected APP nor Aβ levels in H4-APP cells. with of and not However, is of desflurane in to and of Aβ generation. we treatment with 12% (18% O2) for 6 h caspase-3 activation, APP processing, and Aβ generation in H4-APP treatment with 12% desflurane hypoxia alone not to effects in H4-APP cells. desflurane AD neuropathogenesis is treatment with 12% desflurane alone for 6 h effects on and by and in for one and in be to in desflurane is used as inhalation to assess the effects of desflurane on and Aβ generation be to assess alone have effects on and Aβ generation. a broad caspase to caspase-3 and Aβ generation induced by the desflurane/hypoxia-induced in APP and Aβ generation on the of to the by APP processing, and Aβ we the effects of on Desflurane/hypoxia treatment for 6 h increased protein levels of in H4-APP cells. we inhalation in levels to APP and to Aβ generation have to caspase in protein levels of protein a protein and of is with increased levels of and of is to and levels of to levels and to caspase have previously amyloid a and a protein Aβ induced by of Aβ aggregation and generation desflurane/hypoxia-induced caspase-3 in H4-APP cells by the effects of Aβ aggregation and L-685,458 γ-secretase on caspase-3 induced by in H4-APP cells. L-685,458 caspase-3 and Aβ generation induced by also induced by in Aβ generation and aggregation desflurane/hypoxia-induced treatment with Aβ desflurane/hypoxia-induced caspase-3 activation, a of and Aβ generation be by In we have the combination of desflurane and hypoxia, APP processing, and Aβ generation. a in to in and Aβ Aβ levels to caspase activation, in a in be to assess the of desflurane hypoxia in AD neuropathogenesis. to the effects of anesthetics on AD to of to to the of and for a and